Who We Are

IncellDx, Inc. is a single cell diagnostic company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers.



IncellDx technology combines a unique multiplex RNA in situ hybridization method called Simultaneous Ultrasensitive Signal-amplified Hybridization In Situ (SUSHI) with a novel, cell-based instrument capable of quantifying multiple proteins and molecular biomarkers inside intact cells. This allows protein and gene expression to be measured by distinct cell type which aids both diagnosis and disease localization. The company currently has more than 30 issued and pending patents.

The technology is ultra-fast, inexpensive, highly reproducible, and able to perform complex molecular testing without DNA extraction or amplification.



No Positions Available at This Time

Management Team

Chief Executive Officer

Bruce K. Patterson, M.D. is a leading researcher on the effects of viral pathogens on the human immune system. His pioneering technologies and findings have contributed to advances in detection, prognosis and treatment of patients infected with HIV, HPV, cervical cancer, COVID-19 and other diseases.

As Founder and Chief Executive Officer of IncellDx, Inc., Dr. Patterson developed a new paradigm for predicting, identifying and treating long COVID-19 and other viral pathogens that impair the immune system’s ability to function effectively, as well as a patented treatment protocol for long Covid, currently within the application process with the FDA.

Dr. Patterson received his undergraduate degree in microbiology from the University of Michigan and his M.D. from Northwestern University, where he later served as Chief Resident of Pathology at Northwestern Memorial Hospital. He has authored more than 150 manuscripts and book chapters.

Extensive research in Cell Biology, HIV, Covid, Cancer, Immuno-Oncology and
Infectious Diseases with focus on Covid

Associate Professor of Pathology and Infectious Diseases at Stanford University
Director of Virology at Stanford University

B.S., Molecular Biology, University of Michigan
M.D., Northwestern University, Feinberg School of Medicine

Rolling Stone, Science, Scientific America, New England Journal of Medicine

BIO, Discovery Channel, YouTube and various other prime television and multimedia network

Chief Financial Officer

Chris Wheeler is the CFO of InCellDx, Inc. Chris brings a wealth of experience in forming, funding, growing, and ultimately exiting healthcare companies. He is named inventor on many core technologies in the healthcare diagnostics space. He has a Science, Math, Engineering, and Business background and is a results-driven executive who has worked in Silicon Valley for over 20 years.

Chris has founded and owned a large hospital in the Silicon Valley with revenues exceeding $100M per year. He has a proven track record of building successful businesses, managing P&Ls, growing revenue, and sourcing capital. Chris has led projects and programs related to toxicology, large scale health data, cardiac surgery, catheter manufacturing, drug delivery, cancer diagnostics, and several other areas within the healthcare industry.

Chris has success in moving-the-needle on operational improvements at Baxter’s Cardio Vascular Group’s manufacturing plant in Puerto Rico. He implemented a financial and commercialization strategy for a breath-based diagnostics company out of Stanford University. He also has experience commercializing proton beam cancer therapy facilities in both the United States and globally.

Board Member at University of Wisconsin Industrial Advisory Board, where members include well known industry leaders in healthcare, technology, and banking.
Founder and board member at Diagnose Early, Inc.
Actively served on Boards for over 15 years

Education Harvard Business School MBA
University of Wisconsin-Madison BSME, Engineering

Chief Commercial Officer

Throughout his career, Brian Brothen has a proven track record of result-driven business development in the biotech industry. He possesses a keen business acumen and excellent communication, leadership, and problem-solving skills.

Brian leverages his 20+ years of experience consultative sales approaches to revenue-driving and cost-saving solutions in the highly competitive oncology sector. His track record includes developing effective scientific advisory boards, fostering market growth, and establishing strong relationships with key stakeholders.

As the Chief Commercial Officer of IncellDx, Inc., Brian is responsible for establishing critical relationships within the industry and developing opportunities that will set the trajectory of the company.

CytoDyn Senior Vice President Global Oncology, QT Ultrasound LL Vice President, Sales and Business Development, Crown Medical Oncology Chief Commercial Officer/Co-Founder, Paradigm Dx Vice President of Sales, NanoString Technologies, Inc. Business Development Manager, Agendia Director of National Accounts, Pharmion Corporation (BMS) Senior Clinical Oncology Account Manager

University of South Florida, BS, Business/Speech Communications

Sr. Vice President, Strategic Development

Dan Casey is a seasoned commercial leader, who has joined IncellDx as the Senior Vice President of Strategic Development.

With a 25+ year background in building, launching, and leading commercial teams across companies of all sizes, including Sanofi, Emergent BioSolutions, and Galderma Labs, Dan brings expertise in strategic and operational planning, using his deep insights to shape customer and patient engagement models, meticulously plan product launches, navigate change seamlessly and communicate effectively with all audiences.

What truly sets Dan apart is his passion for making a real impact in the world of healthcare and his unwavering commitment to both patients and business growth. Throughout his career, he has consistently balanced prioritizing patient care while delivering impressive financial achievements. As part of the management team, Dan is establishing a sense of accountability, teamwork and revenue growth within the culture of the company.

Vice President, US Commercial, Sanofi Pasteur; Vice President Commercial Development, Sanofi; Vice President North America Travel Medicine Business, Emergent BioSolutions; Vice President US Commercial; Galderma Labs

MBA, Business Administration and Management, Rutgers Business School
BA, Communications, Shippensburg University of Pennsylvania
Executive Coaching Certification, iPEC

Stefan Glück, M.D., PhD, is a medical oncologist specializing in breast, ovarian, and bladder cancers, as well as immunology and hematology. He has led early-stage development studies of solid tumors and immuno-oncology. He has deep expertise in clinical trials, acting as the PI in several dozen.

Dr. Glück has authored/co-authored more than 250 articles, presented more than 350 papers at national and international meetings, and written/co-written multiple book chapters. He is a reviewer of several journals, including the Journal of Clinical Oncology, European Journal of Cancer, Lancet Oncology, Lancet, Breast Cancer Research, The Oncologist, The Breast Journal, and Clinical Breast Cancer.

Dr. Glück was presented the America’s Top Oncologists 2008 award from Consumers’ Research Council of America; he also received the Best Doctors in America honor in since 2006, and has annually earned that prestige every year, including in 2014; this award was warranted after less than 3 years of working in the United States.

Medical Doctor, Regeneron VP and Head Global Franchise Oncology MA, Celgene (BMS) Vice President, GMA Early Assets, University of Miami Sylvester Professor and Assistant Director of the Sylvester Comprehensive Cancer Center, University of Calgary Professor of Oncology, Medicine and Pharmacology

Fraie Universität Berlin, RWTH Aachen University, University of Toronto, Princess Margarete Hospital – Toronto

Photochem Photobiol The selective uptake of benzoporphyrin derivative mono-acid ring A results in differential cell kill of multiple myeloma cells in vitro. June 5, 1996

Breast Cancer Research and Treatment A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer Apr 1, 2012

Biomarkers in Cancers/Libertas Academia Molecular Profiling for Breast Cancer: A Comprehensive Review Oct 29, 2013

Chief Technical Officer

Grace has over twenty years experience in Research & Development and Manufacturing Management in the Medical Device industry. She previously served as Project Manager for Dako, leading international product development teams to launch biological reagents and instrument systems. Earlier, she was responsible for the manufacture and quality control of all molecular pathology reagents manufactured by Dako North America, and has led numerous cross-disciplinary teams to develop molecular pathology probes and detection systems. Knutson previously held staff research positions in virology research laboratories at University of California Santa Barbara and USC Medical School. She received her BA from the University of California at Santa Barbara, and holds a Project Management Professional (PMP®) credential.

Quality Policy


The CEO of IncellDx has issued the following Quality Policy Statement:

IncellDx is committed to developing, manufacturing and distributing products that are of the highest quality available to our customers. To that end, we are committed to meeting or exceeding all applicable quality, regulatory and customer requirements. In order to achieve our objectives, the management team and all the employees at IncellDx are dedicated to improving the continued suitability and effectiveness of our quality management system.